These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1113 related items for PubMed ID: 19780875

  • 1. Adefovir plus lamivudine are more effective than adefovir alone in lamivudine-resistant HBeAg- chronic hepatitis B patients: a 4-year study.
    Vassiliadis TG, Giouleme O, Koumerkeridis G, Koumaras H, Tziomalos K, Patsiaoura K, Grammatikos N, Mpoumponaris A, Gkisakis D, Theodoropoulos K, Panderi A, Katsinelos P, Eugenidis N.
    J Gastroenterol Hepatol; 2010 Jan; 25(1):54-60. PubMed ID: 19780875
    [Abstract] [Full Text] [Related]

  • 2. Adefovir and lamivudine in combination compared with adefovir monotherapy in HBeAg-negative adults with chronic hepatitis B virus infection and clinical or virologic resistance to lamivudine: a retrospective, multicenter, nonrandomized, open-label study.
    Pellicelli AM, Barbaro G, Francavilla R, Romano M, Barbarini G, Mazzoni E, Mecenate F, Paffetti A, Barlattani A, Struglia C, Villani R, Nauri L, Nosotti L, Armignacco O, Ferri F, Camporiondo MP, Soccorsi F, Club Epatologi Ospedalieri (CLEO) Group.
    Clin Ther; 2008 Feb; 30(2):317-23. PubMed ID: 18343270
    [Abstract] [Full Text] [Related]

  • 3. Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy.
    Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, Kim BI.
    J Gastroenterol Hepatol; 2010 Aug; 25(8):1374-80. PubMed ID: 20659226
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B.
    Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ.
    Hepatology; 2007 Feb; 45(2):307-13. PubMed ID: 17256746
    [Abstract] [Full Text] [Related]

  • 6. Comparison of re-treatment outcomes of lamivudine plus adefovir or entecavir in chronic hepatitis B patients with viral relapse after cessation of adefovir.
    Wang JC, He LL, Chen Q.
    Eur Rev Med Pharmacol Sci; 2013 May; 17(9):1162-6. PubMed ID: 23690184
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients.
    Yang DH, Xie YJ, Zhao NF, Pan HY, Li MW, Huang HJ.
    World J Gastroenterol; 2015 Mar 07; 21(9):2746-53. PubMed ID: 25759545
    [Abstract] [Full Text] [Related]

  • 9. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M, Elefsiniotis I, Jardi R, Vargas V, Rodriguez-Frias F, Schapper M, Bonovas S, Esteban R.
    J Hepatol; 2007 Sep 07; 47(3):366-72. PubMed ID: 17561304
    [Abstract] [Full Text] [Related]

  • 10. Clinical course and predictive factors of virological response in long-term lamivudine plus adefovir dipivoxil combination therapy for lamivudine-resistant chronic hepatitis B patients.
    Aizawa M, Tsubota A, Fujise K, Tatsuzawa K, Kono M, Hoshina S, Tajiri H.
    J Med Virol; 2011 Jun 07; 83(6):953-61. PubMed ID: 21503906
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Entecavir 1mg versus combined lamivudine/adefovir dipivoxil in chronic HBV Egyptian patients resistant to LAM monotherapy, non-randomised controlled study.
    Maklad S, Doss W, El Din SS, Hassan K, Zeid AA.
    Arab J Gastroenterol; 2014 Mar 07; 15(1):1-5. PubMed ID: 24630505
    [Abstract] [Full Text] [Related]

  • 13. A short course of add-on adefovir dipivoxil treatment in lamivudine-resistant chronic hepatitis B patients.
    Idilman R, Kaymakoglu S, Oguz Onder F, Ahishali E, Bektas M, Cinar K, Pinarbasi B, Karayalcin S, Badur S, Cakaloglu Y, Mithat Bozdayi A, Bozkaya H, Okten A, Yurdaydin C.
    J Viral Hepat; 2009 Apr 07; 16(4):279-85. PubMed ID: 19222742
    [Abstract] [Full Text] [Related]

  • 14. Virologic responses to add-on adefovir dipivoxil treatment versus entecavir monotherapy in children with lamivudine-resistant chronic hepatitis B.
    Chu M, Cho SM, Choe BH, Cho MH, Kwon S, Lee WK.
    J Pediatr Gastroenterol Nutr; 2012 Dec 07; 55(6):648-52. PubMed ID: 22688509
    [Abstract] [Full Text] [Related]

  • 15. Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B.
    Dai CY, Chuang WL, Hsieh MY, Lee LP, Huang JF, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Tsai JF, Chang WY, Yu ML.
    Antiviral Res; 2007 Aug 07; 75(2):146-51. PubMed ID: 17400303
    [Abstract] [Full Text] [Related]

  • 16. Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine-resistant hepatitis B virus with or without adefovir resistance.
    Yang HJ, Lee JH, Kim YJ, Yoon JH, Lee HS.
    J Med Virol; 2012 Mar 07; 84(3):424-30. PubMed ID: 22246827
    [Abstract] [Full Text] [Related]

  • 17. Treatment response and evolution of HBV resistance during lamivudine plus adefovir or entecavir therapy in patients with adefovir-resistant mutants.
    Chen CH, Wang JH, Lu SN, Hu TH, Hung CH, Chang MH, Changchien CS, Lee CM.
    Antivir Ther; 2012 Mar 07; 17(4):701-9. PubMed ID: 22358132
    [Abstract] [Full Text] [Related]

  • 18. [A clinical study of adefovir dipivoxil in treating lamivudine refractory HBeAg-positive chronic hepatitis B].
    Zhao H, Zhang YX, Chen XY, Wang L, Tang XP, Si CW.
    Zhonghua Nei Ke Za Zhi; 2007 Apr 07; 46(4):294-7. PubMed ID: 17637268
    [Abstract] [Full Text] [Related]

  • 19. [Clinical efficacy of various antiviral-based strategies to treat chronic hepatitis patients with positivity for hepatitis B e antigen and rtN236T mutation].
    Yue W, Yuan H, Mao XR, Deng YD, Chen L.
    Zhonghua Gan Zang Bing Za Zhi; 2013 Mar 07; 21(3):184-8. PubMed ID: 23967738
    [Abstract] [Full Text] [Related]

  • 20. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine.
    Lampertico P, Viganò M, Manenti E, Iavarone M, Lunghi G, Colombo M.
    Hepatology; 2005 Dec 07; 42(6):1414-9. PubMed ID: 16317671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 56.